{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-23-023846","form_type":"8-K","ticker":"PHGE","cik":"0001739174","company_name":"BiomX Inc.","filed_at":"2023-03-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.362845+00:00","generated_at":"2026-06-17T10:41:51.418655+00:00","sec_items":["2.02","5.08","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"BiomX reports Q4 2022 net loss $28.3M; BX004 Part 1 shows >90% bacterial reduction","bullets":["Cash, short-term deposits, restricted cash $34.3M at Dec 31, 2022; cash runway through at least mid-2024.","Net loss for 2022 was $28.3M vs $36.2M in 2021; R&D expenses $16.2M, down from $22.7M.","BX004 Phase 1b/2a Part 1: mean P. aeruginosa reduction of 1.42 log10 CFU/g vs placebo 0.28; no safety events.","Part 2 dosing initiated; results expected Q3 2023; CF Foundation to invest $2M second tranche.","Raised $7.5M private placement in Feb 2023; $6M contingent on shareholder approval; OrbiMed and CF Foundation participated."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-23-023846","json":"https://secwatch.observer/filing/0001213900-23-023846.json","markdown":"https://secwatch.observer/filing/0001213900-23-023846.md","text":"https://secwatch.observer/filing/0001213900-23-023846.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1739174/000121390023023846/0001213900-23-023846-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1739174/000121390023023846/ea175977-8k_biomx.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T10:41:51.418655+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"22be7ac694272cee65917678130836cc9405c7b7","claim":"BiomX Inc. reported financial results for fourth quarter and full year ended December 31, 2022.","evidence_excerpt":"On March 29, 2023, BiomX Inc. (the “Company”) issued a press release announcing its financial results for the fourth quarter ended December 31, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1739174/000121390023023846/0001213900-23-023846-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fourth quarter and full year ended December 31, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}